Literature DB >> 28149892

Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention.

Pradeep Karur1, Dave Singh1.   

Abstract

Entities:  

Year:  2016        PMID： 28149892      PMCID： PMC5233539          DOI： 10.21037/atm.2016.11.58

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  23 in total

1.  Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.

Authors:  Donald A Mahler; Marc Decramer; Anthony D'Urzo; Heinrich Worth; Tracy White; Vijay K T Alagappan; Hungta Chen; Nicola Gallagher; Károly Kulich; Donald Banerji
Journal:  Eur Respir J       Date:  2013-10-31       Impact factor: 16.671

2.  Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

Authors:  Dave Singh; Nicolas Roche; David Halpin; Alvar Agusti; Jadwiga A Wedzicha; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2016-09-01       Impact factor: 21.405

3.  Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.

Authors:  Dave Singh; Alberto Papi; Massimo Corradi; Ilona Pavlišová; Isabella Montagna; Catherine Francisco; Géraldine Cohuet; Stefano Vezzoli; Mario Scuri; Jørgen Vestbo
Journal:  Lancet       Date:  2016-09-01       Impact factor: 79.321

Review 4.  Toward a consensus definition for COPD exacerbations.

Authors:  R Rodriguez-Roisin
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

5.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Authors:  Jadwiga A Wedzicha; Donald Banerji; Kenneth R Chapman; Jørgen Vestbo; Nicolas Roche; R Timothy Ayers; Chau Thach; Robert Fogel; Francesco Patalano; Claus F Vogelmeier
Journal:  N Engl J Med       Date:  2016-05-15       Impact factor: 91.245

6.  Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

Authors:  Bartolome Celli; Glenn Crater; Sally Kilbride; Rashmi Mehta; Maggie Tabberer; Chris J Kalberg; Alison Church
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

7.  LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.

Authors:  Nanshan Zhong; Changzheng Wang; Xiangdong Zhou; Nuofu Zhang; Michael Humphries; Linda Wang; Chau Thach; Francesco Patalano; Donald Banerji
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-05

Review 8.  New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives.

Authors:  Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

9.  Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.

Authors:  Dave Singh; Sally Worsley; Chang-Qing Zhu; Liz Hardaker; Alison Church
Journal:  BMC Pulm Med       Date:  2015-08-19       Impact factor: 3.317

10.  Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).

Authors:  Eric D Bateman; Kenneth R Chapman; Dave Singh; Anthony D D'Urzo; Eduard Molins; Anne Leselbaum; Esther Garcia Gil
Journal:  Respir Res       Date:  2015-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.